Tom Meuleman

Tom Meuleman is an experienced sales and business management professional with a focus on rare diseases and neurology within the BeNeLux region. Currently serving as Sales Manager for Rare & Neurology at UCB since September 2023, Tom also holds the position of Business Unit Manager for Rare Diseases in the same geographic area. With a diverse background, Tom has been a member of the Board of Directors at Mazi Group, Inc. since January 2019 and has consulted for various international biotech startups while serving as Managing Director at Raregenetics.be from September 2015 to August 2023. Previous roles include Commercial Lead for Rare Disease at Vifor Pharma and General Manager for both Amicus Therapeutics and BioMarin. Tom's educational background includes a Master degree in Management with a focus on International Management from Vlerick Business School and a Bachelor degree in Nursing from Katholieke Hogeschool Brugge-Oostende.